TABLE 1.
Demographics of anticholinergic users by study group
| Overall N = 552 |
Intervention sites N = 254 | Usual care sites N = 298 | p-Value for between-group comparisons | |
|---|---|---|---|---|
| Age, mean (SD) | 72.1 (± 6.4) | 71.2 (± 5.9) | 72.9 (± 6.8) | 0.0026 |
| Gender, % female | 442 (80.1%) | 204 (80.3%) | 238 (79.9%) | 0.6353 |
| Race | ||||
| % African American | 250 (45.3%) | 132 (52.0%) | 118 (39.6%) | <0.0001 |
| % Caucasian | 232 (42.0%) | 81 (31.9%) | 151 (50.7% | |
| % other | 70 (12.7%) | 41 (16.1%) | 29 (9.7%) | |
| Coronary artery disease, n (%) | 86 (15.6%) | 33 (13.0%) | 53 (17.8%) | 0.1217 |
| Congestive heart failure, n (%) | 56 (10.1%) | 23 (9.0%) | 33 (11.1%) | 0.4337 |
| Hypertension, n (%) | 471 (85.3%) | 214 (84.2%) | 257 (86.2%) | 0.5103 |
| Diabetes mellitus, n (%) | 251 (45.5%) | 118 (46.4%) | 133 (44.6%) | 0.6677 |
| Cancer, n (%) | 57 (10.3%) | 25 (9.8%) | 32 (10.7%) | 0.7303 |
| Depression, n (%) | 210 (38.0%) | 79 (31.1%) | 131 (44.0%) | 0.0019 |
| Stroke, n (%) | 35 (6.3%) | 12 (4.7%) | 23 (7.7%) | 0.1503 |
| Arthritis, n (%) | 172 (31.2%) | 79 (31.1%) | 93 (31.2%) | 0.9787 |
| Liver disease, n (%) | 35 (6.3%) | 19 (7.5%) | 16 (5.4%) | 0.3104 |
| Renal disease, n (%) | 104 (18.8%) | 51 (20.1%) | 53 (17.8%) | 0.4922 |
| Alzheimer’s and/or dementia, n (%) | 90 (16.3%) | 38 (15.0%) | 52 (17.4%) | 0.4301 |